SCHEMBL17022661

SCHEMBL17022661

O=C(CCC1(Cc2ccc(CC3(CCC(=O)Oc4ccccc4)c4ccccc4-c4ccccc43)cc2)c2ccccc2-c2ccccc21)Oc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APEX1 P27695 1/20 0.54
▸ CYP19A1 P11511 1/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ PRSS1 P07477 1/20 0.39
▸ PRSS2 P07478 1/20 0.39
▸ PRSS3 P35030 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KCNQ2 O43526 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ TDP1 Q9NUW8 2/20 0.37
▸ THRB P10828 1/20 0.37
▸ HSD17B10 Q99714 3/20 0.36
▸ EGFR P00533 1/20 0.36
▸ ERBB2 P04626 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15691583 0.90 APEX1 (0.63) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17022725 0.90 APEX1 (0.63) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL29360310 0.88 APEX1 (0.57) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL15691732 0.88 APEX1 (0.57) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17051262 0.87 APEX1 (0.47) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17022624 0.87 APEX1 (0.59) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17022643 0.87 APEX1 (0.59) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17022516 0.87 APEX1 (0.55) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17050247 0.85 APEX1 (0.54) APEX1CYP19A1KMT2APRSS1PRSS2
SCHEMBL17050248 0.84 APEX1 (0.49) APEX1CYP19A1KMT2APRSS1PRSS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3385300-B1 RESIN COMPOSITION, STRETCHED FILM, CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE MITSUBISHI CHEM CORP (JP) 2020-12-30 — — EP disclosed
CN-106986748-B Oligofluorenediols, oligofluorenediaryl esters, and methods for producing these 三菱化学株式会社 2020-10-09 — — CN disclosed
EP-2910589-B1 RESIN COMPOSITION, STRETCHED FILM , CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE MITSUBISHI CHEM CORP (JP) 2019-09-11 — — EP disclosed
EP-3385300-A1 RESIN COMPOSITION, STRETCHED FILM, CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE Mitsubishi Chemical Corporation (JP) 2018-10-10 — — EP disclosed
US-9518150-B2 Resin composition, stretched film, circularly polarizing plate, and image display device MITSUBISHI CHEMICAL CORPORATION (JP) 2016-12-13 — — US disclosed
US-20150247002-A1 RESIN COMPOSITION, STRETCHED FILM, CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE MITSUBISHI CHEMICAL CORPORATION (JP) 2015-09-03 — — US disclosed
EP-2910589-A1 RESIN COMPOSITION, STRETCHED FILM , CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE Mitsubishi Chemical Corporation (JP) 2015-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150247002-A1 RESIN COMPOSITION, STRETCHED FILM, CIRCULARLY POLARIZING PLATE, AND IMAGE DISPLAY DEVICE RAD50, RAD54L, PUF60 APEX1 3376/4885CYP19A1 3240/4885KMT2A 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback